



General product overview

What is Libra?

Libra is an AI-powered SaaS platform that advances drug-induced liver injury (DILI) risk assessment in preclinical drug development. It combines Certara's expertise in Bayesian machine learning with advanced QSAR techniques to deliver accurate, actionable insights to toxicology teams.

What are the key features of Libra?

- **AI-powered QSAR modeling:** Rapidly assess DILI risk with advanced quantitative structure-activity relationship modeling.
- **Bayesian Predictive Model:** Integrate physicochemical data and in vitro assay data for enhanced risk prediction and decision-making.
- **Flexible inputs:** Modular design adapts to a range of DILI-relevant in vitro assays.
- **Tailored outputs:** Clear graphics and reports for non-specialist audiences.
- **Scalable versions:** Libra (basic model) and Libra max (advanced features).
- **Future expansion:** Potential incorporation of in vivo biomarkers and toxicogenomic markers into the Bayesian model, as well as other DILI-predictive models.

What are the benefits of using Libra?

- Detect DILI risks early in drug discovery, reducing late-stage failures and costs.
- Accessible for non-specialist users (dedicated systems modeler not required).
- Cost-effective compared to competitors, such as DILI-sim.
- Supports more sustainable and ethical research practices by reducing reliance on animal testing.
- Seamless integration into existing workflows for enhanced collaboration.

What is Libra's unique selling proposition (USP)?

Unlike competitors, Libra is intuitive and designed for non-modelers, providing a flexible, rapid and user-friendly approach to DILI risk prediction.

Target audience

Who is Libra designed for?

Libra caters primarily to toxicology groups within large pharmaceutical companies and small biotech organizations seeking smart technology to use themselves or tech-enabled consultancy.

Who are the ideal users within these companies?

- Tox groups in large pharma (e.g., 1-2 licenses per company).
- Small biotech enterprises looking for early-stage drug discovery support (tech-enabled consultancy).
- Users seeking AI-powered insights without requiring dedicated systems modeling expertise.

Competitive comparison

What is Libra's main competitor, and how does it compare?

Competitor: DILI-sim by Simulations+

Key differences

- **Ease of use:** Libra is user-friendly and accessible to non-modelers, while DILI-sim requires a dedicated systems modeler.
- **Commitment:** DILI-sim demands a 3-year consortium commitment (~\$150K/year), whereas Libra offers affordable annual licenses.
- **Flexibility:** Libra allows tailored in vitro assay inputs; DILI-sim requires rigid input parameters.
- **Cost efficiency:** Libra avoids the additional ~\$30K cost for running extra assays needed for DILI-sim.

When is Libra most applicable compared to DILI-sim?

Libra excels during early drug discovery, while DILI-sim is more useful at the first-in-human (FTIH) stage.

Pricing and licensing

What is Libra's pricing structure?

- **Libra (basic):** \$9,000/year for a single user (includes QSAR model and Bayesian ML model).
- **Libra Max (advanced):** \$19,000/year for a single user (includes advanced features like batch testing, auto-generated reports, and data imputation).
- **Additional user licenses:** \$2,500/year per user (both versions).

What is the pricing strategy?

- Enables tight-budget departments to adopt Libra (Basic) while incentivizing upgrades to Libra (Max) for advanced capabilities.
- Competitive pricing structure makes Libra accessible and scalable for a variety of organizations.

Deployment and Integration

How is Libra deployed and accessed?

Libra is a SaaS product hosted on Azure, allowing seamless and secure access via the cloud. It integrates easily into existing workflows, supporting cross-disciplinary collaboration between toxicology, drug discovery, medicinal chemistry, regulatory and translational science teams.

What are the technical differences between Libra and Libra Max?

- **Libra (basic):** Entry-level model with essential features (QSAR, basic Bayesian ML).
- **Libra Max (advanced):** Includes advanced Bayesian analysis, batch-testing, data imputation, and autogenerated reports.

Can Libra be applied even before synthesizing compounds?

Yes! Libra's QSAR model enables DILI hazard identification even before compound synthesis, helping to select safer chemical leads, thereby saving time and resources during the drug discovery phase.

Key Benefits and Proof Points

What challenges does Libra address?

- Flags potential DILI risks early, reducing the number of high-risk compounds advancing unnoticed through the pipeline.
- Tailored to users' DILI strategies, unlike rigid competitor models.
- Enhances cross-disciplinary communication with clear, visually intuitive outputs.

What's a compelling proof point for Libra's effectiveness?

The Bayesian analysis model, foundational to Libra, retrospectively flagged a DILI risk in AstraZeneca's anti-obesity candidate AZD1979—a risk missed using traditional preclinical methods. This misstep cost over \$2M in development and could have been avoided with Libra's predictive analysis. If AZD1979 had reached the market, it had the potential to earn over \$2B annually.

Branding and Differentiation

How does Libra fit into Certara's broader ecosystem?

Libra is part of Certara's ToxStudio® suite, alongside tools like Cardiac Safety Simulator™ and Secondary Intelligence™. Together, these platforms establish Certara as a leader in modernizing preclinical safety assessments with smart in silico innovation.

How does Libra support sustainability?

By reducing reliance on animal testing, Libra aligns with ethical research practices and evolving regulatory standards, ensuring your development process stays ahead of the curve.

Support and Future Development

What support is available to Libra users?

- Ongoing customer support for technical and functional questions.
- Resources for onboarding and best practices to maximize the platform's effectiveness.

What's next for Libra?

Future updates may include in vivo biomarkers and toxicogenomic markers, and a DILI-predictive model mid-way between the QSAR model and the Bayesian model, ensuring Libra continues to evolve as an industry-leading tool in preclinical safety assessment.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Visit certara.com | Copyright ©2025 Certara. All rights reserved.

